Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celgene Corporation

Related CELG
Celgene Announces New Data for OTEZLA® (Apremilast) Will Be Presented at European Academy of Dermatology and Venereology Congress
Concert Pharmaceuticals Announces $8 Million Milestone from Celgene
The Hedged Portfolio Method (GuruFocus)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $91.00 to $94.00.

Jefferies noted, “CELG announced Abraxane met its overall survival primary endpoint in its Phase 3 pancreatic cancer study. We have long considered this indication to be risky and upside to our valuation. Adding pancreatic cancer to our valuation raises our price target from $91 to $94.”

Celgene Corporation closed on Friday at $71.50.

Latest Ratings for CELG

Oct 2015JPMUpgradesNeutralOverweight
Sep 2015JefferiesInitiates Coverage onBuy
Jul 2015Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (CELG)

Get Benzinga's Newsletters